Oral lichen planus: a preliminary clinical study on treatment with tazarotene
Article first published online: 9 OCT 2008
Volume 8, Issue 6, pages 291–295, November 2002
How to Cite
Petruzzi, M., De Benedittis, M., Grassi, R., Cassano, N., Vena, G. and Serpico, R. (2002), Oral lichen planus: a preliminary clinical study on treatment with tazarotene. Oral Diseases, 8: 291–295. doi: 10.1034/j.1601-0825.2002.02833.x
- Issue published online: 9 OCT 2008
- Article first published online: 9 OCT 2008
- Received 5 March 2002; revised 25 June 2002; accepted 27 July 2002
- oral lichen planus;
OBJECTIVE: The rationale for using tazarotene in oral lichen planus (OLP) is its regulatory action on the growth and differentiation of keratinocytes and on inflammation. This randomized, placebo-controlled study addresses evaluation of the effects of topic tazarotene in the treatment of OLP.
DESIGN: The degree of lesions before and after treatment scored by a 6-score scale in six cases treated with tazarotene was statistically compared with those of six controls treated with placebo.
SUBJECTS: Twelve patients with hyperkeratosic OLP were randomly allocated to treatment with tazarotene gel 0.1% b.i.d. or with placebo for eight consecutive weeks.
METHODS: The statistical comparison was executed by means of Wilcoxon analysis for paired data.
RESULTS: Patients treated with tazarotene presented a significant reduction of their lesions as compared with the control group. Among transitory side-effects, burning sensation and taste abnormalities were observed.
CONCLUSION: Topical tazarotene may be a valuable therapeutic tool in the treatment of hyperkeratotic OLP.